Khatib MY, Shaik KS, Ahmed AA, Alwraidat MA, Mohamed AS, Abou Kamar MR, Sharaf Eldean MZ, Aldaraiseh BK, Nashwan AJ. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.
Clin Case Rep 2021;
9:148-152. [PMID:
33489151 PMCID:
PMC7813092 DOI:
10.1002/ccr3.3487]
[Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Revised: 09/25/2020] [Accepted: 10/12/2020] [Indexed: 12/20/2022] Open
Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.
Collapse